FDA, CDER Discuss AI/ML In Drug Development In Discussion Papers
Executive Summary
FDA hopes to engage in “mutual learning” with stakeholders to develop new regulations for the use of AI/ML drug development.
You may also be interested in...
White House Takes Steps To Advance ‘Responsible’ AI That ‘Upholds Democratic Values’
The White House Office of Science and Technology Policy has released an updated national strategic framework outlining priorities and goals for federal investment in AI. Industry executive Peter Shen weighs in on the plan.
News We’re Watching: Two Join Illumina Board, FDA Plans Health Equity Meeting, Pre-Eclampsia Test Cleared
This week, Illumina’s board added two independent members; the VA and the FDA agreed to collaborate on supply chain issues; and Think Surgical, Thermo Fisher Scientific and Blue Earth all landed FDA clearances.
Joint AI/ML Risk Management Guidance Brings FDA Standard To UK
A collaborative document by a US and British organizations brings FDA-approved AI/ML risk management standards to the UK.